AnalystBook Research · Company Intelligence

Atomera Inc

ATOMNasdaq

Built from Atomera Inc's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Atomera revenue fell 51.9% to $65K, losses and FCF worsened, and insiders sold with no buys.

The read at a glance✓ Audited against SEC data
  • Business mixSemiconductor technology licensingNote
  • RevenueRevenue fell 51.9%Watch
  • LossesNet loss widened to $20.2MWatch
  • CashFCF fell to -$14.9MWatch
  • Balance sheetEquity fell 26.7%Watch
  • Insiders0 buys / 7 sellsWatch
  • AccountingAltman-Z distress; EQ greyWatch

Business

Atomera develops and licenses proprietary semiconductor process technology, led by Mears Silicon Technology for improving transistor performance and power efficiency.

Where the revenue comes from

Fiscal 2025, as Atomera Inc reports it. History and quarterly detail are in the app.

  • Timing Of Revenue Recognition$65K
  • Transferred At Point In Time$61K
  • Transferred Over Time$4K

Leadership changes

From Atomera Inc's own filings, the day they're filed.

  • Shawn Thomas · President · departureeff. 2025-03-28
  • Shawn Thomas · President · appointmenteff. 2025-01-22

Latest filings

  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-04
  • 8-K · Company announcement2026-05-13
  • 10-Q · Quarterly report2026-05-05
  • 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Atomera Inc, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.